The research explores why certain aggressive forms of breast cancer do not respond to chemotherapy. By examining the genetic mechanisms behind treatment resistance, the study identifies how specific genes influence cancer behavior and progression. These findings open new possibilities for targeted therapies and more personalized treatment approaches, with the potential to improve patient outcomes.
Supported by a research grant from Al Jalila Foundation, the philanthropic arm of Dubai Health, this important work, titled “The Role of the FOXC1 Gene in Stimulating Aggressive Oncogenic Programs and Chemotherapy Resistance in Triple-negative Breast Cancer through Modulation of Chromatin Availability”, was led by Dr. Shakhzada Ibragimova as part of her PhD journey in the Biomedical Sciences doctoral program at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), the learning and discovery arm of Dubai Health.
Reflecting on her experience, Dr. Shakhzada shared: “Receiving support from Al Jalila Foundation was a turning point for this study, strengthening the research and enabling me to generate meaningful findings that can contribute to improving cancer care. The Foundation’s commitment to advancing scientific discovery gave me the confidence and resources to conduct high-quality research with the potential to make a real difference in patients’ lives.”
This achievement reflects Al Jalila Foundation’s commitment to advancing impactful research and empowering the next generation of scientists whose work can transform lives through discovery.
